First Announcement and Call for Papers
Cambridge Healthtech Institutes 5th annual
Advances in Assays, Molecular Labels, Signaling & Detection
May 17-18, 2001 JW Marriott Hotel, Washington DC
Immediately following CHIs 9th Annual Nucleic Acid-Based Technologies:
PCR and beyond
Researchers are encouraged to submit a proposals for oral (or poster)
presentation.. Proposals from endusers and proposals comparing or
integrating technologies are particularly encouraged. Conference
topics may include new advances in:
Applications
Biomarkers
Diagnostics, especially Field and Point of Care
Drug screening
Genotyping
Molecular pathology
Safety assessment of therapeutics
Proteomics screening
Target validation
Detection
Direct detection
Electronic & electrochemical detection
Electronic noses
High throughput & ultrahigh throughput detection
Homogeneous detection
Mass spectrometry and other detection instrumentation
Optical detection and sensing
Real-time detection
Single molecule detection
Solid phase detection
Technologies
Bioluminescence, chemiluminescence
Biosensors, chemosensors
Dendrimers
Fiber optics
Evanescent wave
Fluorescence
Miniaturization
Microarrays
Multiplexing
Nanoparticles and other advanced labels
Probe design
Protein chips
Signal amplification
Spectroscopy - various
Ultrasensitive technologies
Ultraspecific technologies
Relevant applications include the detection, quantification and
localization of genes and proteins; pathogens; environmental, and a
variety of other targets. Ultrasensitive, ultraspecific, and ultra high
throughput detection have all seen advances in recent years. New
technologies, and improvements in existing instrumentation push the
envelope of detection limits. New probes and labels, homogeneous assay
designs, and direct detection of compounds or specific binding events
are having an impact on applied and basic research, diagnostics, drug
discovery and development, and screening for contaminants and pathogens
in the field. Real-time or reduced time results can payoff in faster
time for clinical trials or by avoiding unnecessary therapy.
Miniaturization, including microarrays and protein chips, promise a
major impact. But cost-effectiveness, reproducibility, robustness, ease
of use and technologies and instrumentation already familiar to existing
staff also factor in analyzing tradeoffs.
Please submit proposals (or suggestions for speakers) by e-mail or fax
to:
Mary Chitty, Conference Director e-mail: mchitty at healthtech.com
fax: 617-630-1325
For full consideration, please submit by December 20, 2000
http://www.healthtech.com
---
